Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Important Concerns Over SARS-CoV-2 Infection in Children With Cancer—Reply

Important Concerns Over SARS-CoV-2 Infection in Children With Cancer—Reply Letters Corresponding Author: David A. Reardon, MD, Dana-Farber/Harvard Cancer targeting agents because of potential false responses owing to 2 Center, 450 Brookline Ave, D2134, Boston, MA 02215-5450 (david_reardon@ their effect on contrast uptake. Therefore, further value is dfci.harvard.edu). added if the response is maintained for a meaningful dura- Published Online: October 8, 2020. doi:10.1001/jamaoncol.2020.4664 tion. Longer DOR has been consistently noted following anti– Conflict of Interest Disclosures: Dr Weller reported receiving patient fees from programmed cell death 1 (PD-1) therapy across tumor types, Bristol Myers Squibb; grants from Adastra Pharmaceuticals and Novocure; explained by generation of polyclonal and memory-adaptive grants and personal fees from AbbVie, Merck Sharp & Dohme, Merck (EMD), and Philogen; and personal fees from Orbus Pharma, Basilea Pharmaceutica, tumor immunity. Therefore, DOR is an increasingly impor- Medac Pharma, Celgene, Nerviano Medical Sciences, Roche, and Tocagen. tant end point, in addition to ORR, for evaluating the efficacy Dr Reardon reported receiving grants from Acerta Pharma, Incyte, Midatech and long-term clinical benefit of immunotherapy. Given the Pharma, Omniox, and Tragara Pharmaceuticals; grants and personal fees from above rationale, we presented a descriptive summary of DOR. Agenus, Celldex Therapeutics, EMD Serono, and Inovio Pharmaceuticals; personal fees from AbbVie, Advantagene, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Important Concerns Over SARS-CoV-2 Infection in Children With Cancer—Reply

JAMA Oncology , Volume 6 (12) – Dec 15, 2020

Loading next page...
 
/lp/american-medical-association/important-concerns-over-sars-cov-2-infection-in-children-with-cancer-agdOopNY1A
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.4767
Publisher site
See Article on Publisher Site

Abstract

Letters Corresponding Author: David A. Reardon, MD, Dana-Farber/Harvard Cancer targeting agents because of potential false responses owing to 2 Center, 450 Brookline Ave, D2134, Boston, MA 02215-5450 (david_reardon@ their effect on contrast uptake. Therefore, further value is dfci.harvard.edu). added if the response is maintained for a meaningful dura- Published Online: October 8, 2020. doi:10.1001/jamaoncol.2020.4664 tion. Longer DOR has been consistently noted following anti– Conflict of Interest Disclosures: Dr Weller reported receiving patient fees from programmed cell death 1 (PD-1) therapy across tumor types, Bristol Myers Squibb; grants from Adastra Pharmaceuticals and Novocure; explained by generation of polyclonal and memory-adaptive grants and personal fees from AbbVie, Merck Sharp & Dohme, Merck (EMD), and Philogen; and personal fees from Orbus Pharma, Basilea Pharmaceutica, tumor immunity. Therefore, DOR is an increasingly impor- Medac Pharma, Celgene, Nerviano Medical Sciences, Roche, and Tocagen. tant end point, in addition to ORR, for evaluating the efficacy Dr Reardon reported receiving grants from Acerta Pharma, Incyte, Midatech and long-term clinical benefit of immunotherapy. Given the Pharma, Omniox, and Tragara Pharmaceuticals; grants and personal fees from above rationale, we presented a descriptive summary of DOR. Agenus, Celldex Therapeutics, EMD Serono, and Inovio Pharmaceuticals; personal fees from AbbVie, Advantagene,

Journal

JAMA OncologyAmerican Medical Association

Published: Dec 15, 2020

References